Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study

A. Guerrieri-Gonzaga, E. Botteri, M. Lazzeroni, N. Rotmensz, A. Goldhirsch, C. Varricchio, D. Serrano, M. Cazzaniga, F. Bassi, A. Luini, V. Bagnardi, G. Viale, S. Mora, G. Bollani, E. Albertazzi, B. Bonanni, A. Decensi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. Patients and methods: A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. Results: Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR 50% DIN, recurrence was higher in PgR ≥50% DIN than in PgR

Original languageEnglish
Pages (from-to)949-954
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number5
DOIs
Publication statusPublished - Oct 25 2009

Keywords

  • Breast cancer
  • DCIS
  • Ductal intraepithelial neoplasia
  • Low-dose tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study'. Together they form a unique fingerprint.

Cite this